Inhibikase Therapeutics, Inc.

Initiate a Phase 1b study for IkT-148009

Deadline passed; outcome being checked

Announced: 8 Feb 2021
Due: 8 Feb 2022
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“The Company anticipates initiating a Phase 1 b study in treatment naïve and early stage Parkinson’s patients with GI complications for IkT - 148009 in the next 12 months subject to additional financing.”

SourceInhibikase Therapeutics, Inc. Form 8-K press release, 2021-02-08
FilingSEC filing index
Deadline as statedin the next 12 months
Deadline used8 Feb 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-IKT-023246
Cite as https://keptindex.org/c/KI-C-2021-IKT-023246/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 1b study for IkT-148009
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High
Conditional: Yes: subject to additional financing
Depends on: Financing

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Inhibikase Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-IKT-023246 · Corrections policy